Literature DB >> 32861448

Biliary atresia: East versus west.

Patrick Ho Yu Chung1, Shan Zheng2, Paul Kwong Hang Tam3.   

Abstract

Biliary atresia (BA) is a common cause of surgical jaundice during the neonatal period. It is currently considered as a spectrum of diseases with a common final pathology characterized by obliteration of the extrahepatic biliary tract and the absence of normally branching intrahepatic ducts. Though it is a global disease that can be found in all ethnicities there are some clear differences between BA arising in the East and the West. This is likely to be related to different genetic, environmental and cultural factors. BA is more frequently found in Far Eastern infants (both Chinese and Japanese) though the syndromic associations are much less common. Many Eastern countries have national screening programmes not seen in the West possibly due to debate over its cost effectiveness in countries where incidence is low. Kasai portoenterostomy (KPE) is considered as the primary treatment of BA but its outcome still remains unsatisfactory across the region. Given the complexity of BA, it is unlikely that strategic advances could be made by the sole effort of individual countries and we believe that collaboration between the East and West is the way forward.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Biliary atresia; Biliary atresia splenic malformation syndrome; Kasai portoenterostomy; Liver transplant

Mesh:

Year:  2020        PMID: 32861448     DOI: 10.1016/j.sempedsurg.2020.150950

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  7 in total

1.  Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia.

Authors:  Hoa Pham Anh Nguyen; Jinma Ren; Marilyn Butler; Henri Li; Saqib Qazi; Kamran Sadiq; Hieu Trung Dao; AiXuan Holterman
Journal:  Pediatr Surg Int       Date:  2022-04-07       Impact factor: 1.827

Review 2.  Biliatresone: progress in biliary atresia study.

Authors:  Jia-Jie Zhu; Yi-Fan Yang; Rui Dong; Shan Zheng
Journal:  World J Pediatr       Date:  2022-09-27       Impact factor: 9.186

3.  Biliary Atresia in 2021: Epidemiology, Screening and Public Policy.

Authors:  Richard A Schreiber; Sanjiv Harpavat; Jan B F Hulscher; Barbara E Wildhaber
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

4.  Developing Biliary Atresia-like Model by Treating Human Liver Organoids with Polyinosinic:Polycytidylic Acid (Poly (I:C)).

Authors:  Patrick Ho-Yu Chung; Rosana Ottakandathil Babu; Zhongluan Wu; Kenneth Kak-Yuen Wong; Paul Kwong-Hang Tam; Vincent Chi-Hang Lui
Journal:  Curr Issues Mol Biol       Date:  2022-01-27       Impact factor: 2.976

5.  Biomarkers for the diagnosis and post-Kasai portoenterostomy prognosis of biliary atresia: a systematic review and meta-analysis.

Authors:  Lin He; Dennis Kai Ming Ip; Greta Tam; Vincent Chi Hang Lui; Paul Kwong Hang Tam; Patrick Ho Yu Chung
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

6.  Plasma amyloid-beta levels correlated with impaired hepatic functions: An adjuvant biomarker for the diagnosis of biliary atresia.

Authors:  Hongyu Lyu; Yongqin Ye; Vincent Chi Hang Lui; Weifang Wu; Patrick Ho Yu Chung; Kenneth Kak Yuen Wong; Hung-Wing Li; Man Shing Wong; Paul Kwong Hang Tam; Bin Wang
Journal:  Front Surg       Date:  2022-09-05

7.  Low gamma-glutamyl transpeptidase levels at presentation are associated with severity of liver illness and poor outcome in biliary atresia.

Authors:  Song Sun; Shan Zheng; Chun Shen; Rui Dong; Kuiran Dong; Jingying Jiang; Yifan Yang; Gong Chen
Journal:  Front Pediatr       Date:  2022-09-23       Impact factor: 3.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.